Key result
Omega-3 PUFA lowers NT-proBNP and improves lipid profiles in diabetic cardiovascular autonomic neuropathy.
Why the study?
Cardiac autonomic neuropathy in type 2 diabetes mellitus is an independent risk factor for cardiovascular mortality, and the effect of long-chain omega-3 PUFA on NT-proBNP and lipid profile in this population was analyzed.
Does long-chain omega-3 PUFA improve NT-proBNP and lipid profile parameters in patients with T2DM and cardiac autonomic neuropathy?
Does long-chain omega-3 PUFA improve NT-proBNP and lipid profile parameters in patients with T2DM and cardiac autonomic neuropathy?
The addition of 1 g/day of omega-3 PUFA to standard hypoglycemic therapy for three months significantly improved NT-proBNP and lipid profiles in patients with T2DM and cardiac autonomic neuropathy.
May support ω-3 PUFA in T2DM with CAN; leaves open effects on NT-proBNP and lipids pending larger trials.
Background and Aims: Cardiac autonomic neuropathy (CAN) in type 2 diabetes mellitus (T2DM) is one of the independent risk factor for cardiovascular mortality. The aim of the study was to analyze the effect of long-chain w-3 polyunsaturated fatty acids (w-3 PUFA) on the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and on some lipid profile parameters in patients with T2DM and CAN. Material and Methods: 36 patients with T2DM and verified CAN were divided into 2 groups. The first group received traditional hypoglycemic therapy (n = 15, control) for three months; patients in group 2 (n = 21) received in addition 1 g/day of the long-chain w-3 PUFA for three months. Results: Prescription of the w-3 PUFA to the patients with T2DM and СAN was accompanied by a statistically significant decrease of NT-proBNP level and led to significantly positive changes in the high density lipoprotein cholesterol and triglycerides levels in the blood. Conclusions: Obtained results suggest that the efficacy of w-3 PUFA is the result of a direct effect of the pharmacological agent on the investigated indexes
No takes yet. Share an insight, caveat, or question.
Serhiyenko et al. (2014) studied Type 2 diabetes mellitus and cardiovascular autonomic neuropathy (n=36). long-chain w-3 polyunsaturated fatty acids (w-3 PUFA) vs. traditional hypoglycemic therapy was evaluated on levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and lipid profile parameters. Addition of 1 g/day of long-chain w-3 PUFA for three months significantly decreased NT-proBNP and improved HDL and triglyceride levels in patients with T2DM and cardiovascular autonomic neuropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: